Proposed biosimilar drug shows potential as breast cancer treatment

(The JAMA Network Journals) Among women with metastatic breast cancer, treatment with a drug that is biosimilar to the breast cancer drug trastuzumab resulted in an equivalent overall response rate at 24 weeks compared with trastuzumab, according to a study published online by JAMA.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news